[US Stock Movement] Kodiak Sciences surged on September 30: DAYBREAK meets standards + retinal drug

Kodiak Sciences September 30 Surge Interpretation

Keywords: DAYBREAK target met, retinal drug

1. On September 28, the company announced results from the pivotal Phase 3 DAYBREAK trial. Both Zenkuda and tabirafusp-tedKSI-501 achieved the primary endpoint in patients with wet age-related macular degeneration; Zenkuda demonstrated visual gains non-inferior to aflibercept, with a primary endpoint p-value of 0.0007, while KSI-501's visual primary endpoint p-value was 0.0036.

2. On September 28, Zenkuda demonstrated rapid and long-lasting clinical effects. Under stringent retreatment criteria, 54% of patients achieved six-month dosing durability at one year; the company plans to submit a biologics license application for Zenkuda in the fourth quarter of 2026.

3. On September 29, multiple institutions updated their ratings and price targets for Kodiak Sciences, with the price target range between $96 and $145; UBS raised its price target from $80 to $120, and Jefferies raised its target from $56 to $112.

(Disclaimer: This content is generated by AI summarizing publicly available information and is for reference only. It does not constitute investment advice.)